Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meglumine antimoniate plus allopurinol versus meglumine antimoniate alone for cutaneous leishmaniasis
IRCT20210823052264N6Phase 3Completed
- Sponsor
- Combined Military Hospital Quetta
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of meglumine antimoniate and allopurinol in cutaneous leishmaniasis (CL) (2 arms), sponsored by Combined Military Hospital Quetta. Primary endpoint: Clinical/treatment response. Started May 2024; status: completed.
02
Drugs
meglumine antimoniateallopurinol
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on IRCT20210823052264N6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210823052264N6.